1. Home
  2. CVSA vs ACAD Comparison

CVSA vs ACAD Comparison

Compare CVSA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CVSA

Covista Inc. Common Shares

N/A

Current Price

$132.25

Market Cap

3.9B

Sector

Real Estate

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.41

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVSA
ACAD
Founded
1987
1993
Country
United States
United States
Employees
4996
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CVSA
ACAD
Price
$132.25
$22.41
Analyst Decision
Strong Buy
Buy
Analyst Count
2
22
Target Price
$150.00
$30.55
AVG Volume (30 Days)
222.2K
1.5M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
0.02
Revenue
N/A
$726,437,000.00
Revenue This Year
$9.66
$18.80
Revenue Next Year
$6.58
$11.70
P/E Ratio
N/A
$1,127.50
Revenue Growth
N/A
40.45
52 Week Low
$96.08
$19.69
52 Week High
$119.41
$28.35

Technical Indicators

Market Signals
Indicator
CVSA
ACAD
Relative Strength Index (RSI) 72.12 51.62
Support Level $111.20 $21.04
Resistance Level N/A $22.91
Average True Range (ATR) 5.08 0.73
MACD 0.99 0.03
Stochastic Oscillator 95.08 55.56

Price Performance

Historical Comparison
CVSA
ACAD

About CVSA Covista Inc. Common Shares

Covista Inc is an American healthcare educator, serving more than 97,000 students and supported by a community of alumni across five accredited institutions. Through personalized, tech-enabled education powered by faculty and colleagues, it expands access to healthcare careers and addresses the U.S. healthcare workforce shortage at scale.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: